At a 15.6 times P/E, Regeneron is relatively expensive compared to out of favor biotechnology stocks. This includes Allergan (AGN), with a forward P/E of 8 times; Teva Pharmaceuticals (TEVA), with …
More Assessing If Regeneron Is In Value Territory After Shares Tumble Videos